Advertisement

Drugs & Therapy Perspectives

, Volume 5, Issue 10, pp 7–9 | Cite as

Topoisomerase I inhibitors: a novel class of antineoplastic drugs

New Drugs and Therapeutics
  • 5 Downloads

Keywords

Irinotecan Hepatic Encephalopathy Topotecan Lactulose Advanced Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sinha BK. Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs 1995 Jan; 49(1): 11–9PubMedCrossRefGoogle Scholar
  2. 2.
    Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993 Feb 17; 85(4): 271–91PubMedCrossRefGoogle Scholar
  3. 3.
    Lee R. Irinotecan — a novel drug for treating colorectal cancer. Inpharma 1995 Feb 11; (973): 9–10Google Scholar
  4. 4.
    Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994 Jan; 20: 73–96PubMedCrossRefGoogle Scholar
  5. 5.
    Wagener DJTh, Verdonk HER, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995 Feb; 6: 129–32PubMedGoogle Scholar
  6. 6.
    Tsuda H, Takatsuki K, Ohno R, et al. Treatment of adult T-cell leukaemialymphoma with irinotecan hydrochloride (CPT-11). Br J Cancer 1994 Oct; 70: 771–4PubMedCrossRefGoogle Scholar
  7. 7.
    Lynch Jr TJ, Kalish L, Strauss G, et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994 Feb; 12(2): 347–52PubMedGoogle Scholar
  8. 8.
    O’Brien S, Kantarjian H, Ellis A, et al. Topotecan in chronic lymphocytic leukaemia. Cancer 1995 Mar 1; 75: 1104–8PubMedCrossRefGoogle Scholar
  9. 9.
    Hochster H, Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994 Mar; 12(3): 553–9PubMedGoogle Scholar
  10. 10.
    Shimada Y, Sasaki Y, Sugano K, et al. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil in metastatic colorectal cancer [abstract]. Proceedings ASCO 1993 Mar; 312: 196Google Scholar
  11. 11.
    Sasaki Y, Ohtsu A, Shimada Y, et al. Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994 Jul 20; 86: 1096–8PubMedCrossRefGoogle Scholar
  12. 12.
    Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cis-platin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 1994 Jan; 12(1): 90–6PubMedGoogle Scholar
  13. 13.
    Abigerges D, Chabot GG, Armand J-P, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995 Jan; 13(1): 210–22PubMedGoogle Scholar
  14. 14.
    de Forni M, Bugat R, Chabot GG, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994 Aug 15; 54: 4347–54PubMedGoogle Scholar
  15. 15.
    Catimel G, Chabot GG, Gustalla JP, et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995 Feb; 6: 133–40PubMedGoogle Scholar
  16. 16.
    Irinotecan link with fatalities. Reactions 1994 Mar 5; (491): 2Google Scholar

Copyright information

© Adis International Limited 1995

Personalised recommendations